Tekla Life Sciences Investors (HQL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tekla Life Sciences Investors (HQL) has a cash flow conversion efficiency ratio of -0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.28 Million) by net assets ($513.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Tekla Life Sciences Investors fund operations to measure how many days the company can operate on defensive assets alone.
Tekla Life Sciences Investors - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Tekla Life Sciences Investors's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tekla Life Sciences Investors Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tekla Life Sciences Investors ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Levinstein Eng
TA:LEVI
|
0.001x |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
0.036x |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
-0.021x |
|
Jiangsu Fasten Co Ltd
SHE:000890
|
0.332x |
|
Yantai Ishikawa Sealing Technology Co.Ltd.
SHE:301020
|
0.002x |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
0.030x |
|
Beijing Tieke Shougang Railway Tech Co Ltd
SHG:688569
|
0.065x |
|
GFT Technologies SE
XETRA:GFT
|
0.016x |
Annual Cash Flow Conversion Efficiency for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual cash flow conversion efficiency of Tekla Life Sciences Investors from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see HQL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $513.66 Million | $-2.32 Million | -0.005x | -319524554.28% |
| 2021-09-30 | $523.44 Million | $-0.74 | 0.000x | +12.40% |
| 2019-09-30 | $384.16 Million | $-0.62 | 0.000x | +100.00% |
| 2014-09-30 | $444.09 Million | $-52.57K | 0.000x | -477.75% |
| 2013-09-30 | $302.29 Million | $9.47K | 0.000x | -99.97% |
| 2012-09-30 | $227.08 Million | $21.11 Million | 0.093x | -86.60% |
| 2011-09-30 | $170.60 Million | $118.30 Million | 0.693x | +9075.24% |
| 2010-09-30 | $251.40 Million | $1.90 Million | 0.008x | -85.55% |
| 2009-09-30 | $248.60 Million | $13.00 Million | 0.052x | +23.11% |
| 2008-09-30 | $277.80 Million | $11.80 Million | 0.042x | +453.59% |
| 2007-09-30 | $308.00 Million | $-3.70 Million | -0.012x | -53.37% |
| 2006-09-30 | $268.10 Million | $-2.10 Million | -0.008x | +43.87% |
| 2005-09-30 | $229.30 Million | $-3.20 Million | -0.014x | +16.35% |
| 2004-09-30 | $191.80 Million | $-3.20 Million | -0.017x | -32.36% |
| 2003-09-30 | $190.40 Million | $-2.40 Million | -0.013x | +23.59% |
| 2002-09-30 | $157.60 Million | $-2.60 Million | -0.016x | -86.77% |
| 2001-09-30 | $215.10 Million | $-1.90 Million | -0.009x | +48.04% |
| 1998-09-30 | $100.00 Million | $-1.70 Million | -0.017x | -49.60% |
| 1997-09-30 | $132.00 Million | $-1.50 Million | -0.011x | +6.74% |
| 1996-09-30 | $123.10 Million | $-1.50 Million | -0.012x | -- |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more